GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Longboard Pharmaceuticals
LeddarTech is a developer of sensor technologies for the automotive industry. Its stock price is a bet that its solutions will be chosen for advanced driver assistance systems (ADAS). The chart reflects the intense competition in this sector.
Share prices of companies in the market segment - Neuro
Longboard Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare neurological and epileptic disorders. We've categorized it as a "Neurology" stock. The chart below reflects how investors assess the risks and prospects in this complex area of medicine.
Broad Market Index - GURU.Markets
Longboard Pharmaceuticals is a biotech company developing drugs to treat rare neurological diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Longboard shares correlate with sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
LBPH - Daily change in the company's share price Longboard Pharmaceuticals
For Longboard Pharmaceuticals, Inc., a neuroscience company, daily price change is a measure of its enormous volatility. The metric reflects its extreme sensitivity to clinical trial data for its epilepsy drugs.
Daily change in the price of a set of shares in a market segment - Neuro
Longboard Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare neurological diseases. Neurology is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with LBPH's developments.
Daily change in the price of a broad market stock, index - GURU.Markets
Longboard Pharmaceuticals is a biotech company working on treatments for neurological diseases. Its shares represent a venture capital bet on scientific success. Their high volatility, driven by expectations, contributes to the overall stock market's performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Longboard Pharmaceuticals
Longboard Pharmaceuticals' year-to-date performance is a story of drug development for rare neurological diseases. Its 12-month market cap is entirely dependent on clinical trial data. Success with its lead epilepsy candidate could be a breakthrough and offer new hope for patients.
Annual dynamics of market capitalization of the market segment - Neuro
Longboard, a late-stage biotech company, develops drugs for the treatment of neurological diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Longboard Pharmaceuticals, a company developing drugs to treat rare neurological diseases, is a classic biotech company. Its year-over-year market capitalization reflects investor expectations for clinical trial results rather than economic cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Longboard Pharmaceuticals
Longboard is a biopharmaceutical company focused on neurological diseases. Its monthly performance is entirely dependent on progress in its clinical programs. News of its drug trial results is the main driver.
Monthly dynamics of market capitalization of the market segment - Neuro
This chart reflects the dynamics of the biotech sector, particularly in neuroscience. For Longboard, a clinical-stage company, it's the backdrop. Its volatile movements demonstrate how investor expectations surrounding the results of its drug trials are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Longboard Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare neurological diseases. Its value depends almost entirely on the success of clinical trials. The overall market has little impact on Longboard; its shares are driven by scientific news, which can cause explosive gains or losses on any given day.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Longboard Pharmaceuticals
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating rare neurological diseases. Its weekly stock price is highly volatile and depends on news of clinical trial results.
Weekly dynamics of market capitalization of the market segment - Neuro
Longboard Pharmaceuticals develops drugs to treat rare neurological diseases. This is a highly specialized niche in the pharmaceutical industry. The chart will show whether the company's stock price performance is related to its own clinical trials or reflects general trends in the orphan disease sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Longboard is a biotech company whose stock moves on news about clinical trials. This chart clearly demonstrates how much its performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
LBPH - Market capitalization of the company Longboard Pharmaceuticals
The market capitalization of Longboard Pharmaceuticals, a spinoff of Arena Pharmaceuticals, reflects its focus on developing drugs for rare neurological diseases. Its volatile price is driven by news about the progress of its clinical trials. This represents a high-risk bet on its scientific platform.
LBPH - Share of the company's market capitalization Longboard Pharmaceuticals within the market segment - Neuro
Longboard Pharmaceuticals is a biotech company specializing in developing drugs for rare neurological diseases. Its market share in the pharmaceutical sector is very small. Its market capitalization reflects investors' assessment of its development pipeline, inherited from its parent company, and the market potential of these drugs.
Market capitalization of the market segment - Neuro
The chart below shows the market capitalization of the neurological pharmaceuticals sector. Longboard Pharmaceuticals, a spinoff from Arena Pharma, is focused on developing drugs to treat rare epilepsy syndromes. Its market performance exemplifies how to focus efforts on highly specific yet important medical needs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Longboard is a biopharmaceutical company developing drugs to treat rare neurological diseases. Its market capitalization reflects the potential of its research in this complex field. The chart below shows the economic weight of companies at the forefront of neuroscience.
Book value capitalization of the company, segment and market as a whole
LBPH - Book value capitalization of the company Longboard Pharmaceuticals
Longboard Pharma's book value is derived from its equity and the intellectual property in its portfolio of drugs for rare neurological diseases. The chart shows the story of the biotech company, which was spun out of Arena Pharma and now independently invests in the clinical trials of its promising candidates.
LBPH - Share of the company's book capitalization Longboard Pharmaceuticals within the market segment - Neuro
Longboard Pharmaceuticals develops drugs to treat rare neurological diseases. The chart shows its share of actual R&D assets. These are its laboratories where work is underway to create new drugs to improve patients' quality of life.
Market segment balance sheet capitalization - Neuro
Longboard Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neurological diseases. Their value is created in laboratories. The book value chart reflects the value of their R&D base but fails to convey the potential value of their intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Longboard Pharmaceuticals' resources include laboratories and R&D centers for developing drugs to treat rare epilepsy syndromes. The chart shows how the company built its scientific and physical capital.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Longboard Pharmaceuticals
Longboard Pharmaceuticals is a biotech company focused on neurological diseases. Its assets are a portfolio of molecules acquired from Arena Pharmaceuticals. The chart below represents a bet on the success of these developments. Market capitalization reflects the potential of these drugs, not current assets.
Market to book capitalization ratio in a market segment - Neuro
Longboard Pharmaceuticals is a biotech company specializing in developing drugs for rare neurological diseases. Its valuation is dependent on the success of its clinical trials. The timeline reflects the high risk and expectations associated with developing drugs for complex and poorly understood diseases.
Market to book capitalization ratio for the market as a whole
Longboard Pharmaceuticals is a biotech company focused on neurological diseases. Its value depends almost entirely on the success of its clinical programs. This chart shows the vast gap between the market valuation based on the future potential of its drugs and its current book value.
Debts of the company, segment and market as a whole
LBPH - Company debts Longboard Pharmaceuticals
Longboard Pharmaceuticals, a spinoff from Arena Pharmaceuticals, develops drugs for rare neurological diseases. This chart shows its financial model. The company uses capital received from its parent company to advance its pipeline of candidates through clinical trials.
Market segment debts - Neuro
Longboard Pharmaceuticals is a biotech company focused on rare neurological diseases. It was spun out of Arena Pharmaceuticals. This chart reflects the company's financial strategy during the clinical development phase, when it must prove the efficacy of its legacy developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Longboard Pharmaceuticals
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on neuroscience. This chart shows its financial structure. For a company whose drugs have not yet reached the market, any debt is a significant risk.
Market segment debt to market segment book capitalization - Neuro
Longboard Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neurological diseases. This chart shows the debt load in the biotech sector. It is an indicator of the company's ability to finance its expensive clinical research and development in this complex area of medicine.
Debt to book value of all companies in the market
Longboard Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare neurological diseases. Developing such drugs is a lengthy and expensive process. This chart of total market debt shows how willing the financial system is to finance such long-term, high-risk scientific projects.
P/E of the company, segment and market as a whole
P/E - Longboard Pharmaceuticals
Longboard Pharmaceuticals is a biotech company focused on developing drugs for rare neurological diseases. This chart reflects investor expectations for its clinical programs. The dynamics are entirely dependent on trial results and are not related to current financial performance.
P/E of the market segment - Neuro
Longboard Pharmaceuticals is a clinical-stage biotech focused on developing drugs to treat rare neurological diseases, such as epileptic encephalopathies. This chart shows the average valuation for the neurology sector, reflecting how investors value companies working to solve complex problems in pediatric neurology.
P/E of the market as a whole
Longboard Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of neurological disorders. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. The overall market sentiment reflected in this chart is completely irrelevant for the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Longboard Pharmaceuticals
Longboard Pharmaceuticals is a biotech company developing drugs for rare neurological diseases. This chart reflects market expectations for the success of its clinical programs. Future profits are entirely dependent on the results of trials and regulatory approvals of its drug candidates.
%20P%2FE%20Longboard%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Longboard-Pharmaceuticals&v=1772610132516 "Chart of the company's future (projected) P/E Longboard Pharmaceuticals")
Future (projected) P/E of the market segment - Neuro
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for rare neurological diseases. The chart reflects average profitability expectations for the biotech sector. LBPH's position relative to this benchmark reflects investors' bet on its scientific approach and success in clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772610132523 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecules for the treatment of rare neurological diseases. The company was spun out of Arena Pharmaceuticals. This chart of overall market expectations illustrates investor appetite for the risk associated with funding long and complex clinical trials in CNS diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772610132524 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Longboard Pharmaceuticals
Longboard Pharmaceuticals is a clinical-stage biotechnology company developing drugs for the treatment of rare neurological diseases. Its financial schedule is driven by research and development expenses. Potential profitability depends entirely on the success of its candidates in clinical trials.
Profit of companies in the market segment - Neuro
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of rare neurological diseases, including epilepsy. This chart shows the total revenue in its sector, illustrating the level of investor confidence in the commercial potential of its developments for the treatment of complex and rare diseases of the central nervous system.
Overall market profit
Longboard Pharmaceuticals is a biotech company developing drugs to treat rare neurological diseases. Its value and prospects depend on the success of its clinical trials. The overall market situation, reflected in this chart, directly impacts its ability to raise capital to fund its research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Longboard Pharmaceuticals
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare neurological diseases. This chart reflects analysts' speculative expectations regarding the potential of its pipeline of candidates acquired from Arena Pharmaceuticals.
%20profit%20of%20the%20company%20Longboard%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Longboard-Pharmaceuticals&v=1772610132578 "Graph of future (projected) profit of the company Longboard Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Neuro
Longboard Pharmaceuticals is a biotech company developing drugs to treat rare neurological disorders. Its future depends on successful clinical trials and scientific breakthroughs. This chart reflects profitability forecasts for the entire pharmaceutical sector, allowing you to assess Longboard's potential in this complex and important area of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772610132584 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Longboard Pharmaceuticals is a biopharmaceutical company focused on treating neurological diseases. Its success depends on clinical trial results and regulatory approval. The overall economic projections shown in this chart are of minimal importance to the company at this stage.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772610132585 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Longboard Pharmaceuticals
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the treatment of neurological diseases. Its high valuation, as shown in this chart, is based on the potential of its pipeline. Its performance is entirely dependent on clinical trial results and regulatory updates.
P/S market segment - Neuro
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for rare neurological diseases. Future revenue is dependent on the success of its clinical programs. This neuroscience chart reflects investor expectations for the potential of Longboard's pipeline.
P/S of the market as a whole
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare neurological diseases. This market revenue valuation chart helps understand how investors view the company's potential in this complex yet important area of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Longboard Pharmaceuticals
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of rare neurological diseases. This chart shows how the market assesses the future commercial potential of its pipeline. It reflects investor expectations for the success of its clinical trials.
%20P%2FS%20Longboard%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Longboard-Pharmaceuticals&v=1772610132662 "The graph of the company's future (projected) P/S Longboard Pharmaceuticals")
Future (projected) P/S of the market segment - Neuro
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare neurological diseases. The company, spun out of Arena Pharmaceuticals, is valued based on investors' confidence in the potential of its pipeline of candidates, representing a high-risk bet on success in complex clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772610132666 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Longboard Pharmaceuticals is a biotech company focused on treating rare neurological diseases. Its prospects depend on the success of clinical trials. In the context of the overall revenue projections shown in the chart, Longboard represents a venture capital investment in the future of neuroscience.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772610132667 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Longboard Pharmaceuticals
Longboard Pharmaceuticals is a clinical-stage biotechnology company developing treatments for neurological diseases. The company currently has no commercial products and, consequently, no sales revenue. It was spun out of Arena Pharmaceuticals to continue its development.
Sales of companies in the market segment - Neuro
Longboard Pharmaceuticals (LBPH) is a biopharmaceutical company focused on developing new treatments for rare and severe neurological diseases. This chart shows revenue in the neurological pharmaceutical segment. Longboard strives to develop targeted therapies for patients suffering from epilepsy and other disorders with high unmet medical needs.
Overall market sales
Longboard Pharmaceuticals is a biotech company focused on developing drugs to treat rare neurological diseases. Its success depends on the results of clinical trials. This pattern of overall economic activity influences the investment climate. During periods of growth, investors are more inclined to fund companies targeting orphan diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Longboard Pharmaceuticals
Longboard Pharmaceuticals is a biotech company developing drugs for the treatment of rare neurological diseases. Future revenue depends on the success of its clinical trials. This chart reflects analyst forecasts, which essentially assess the scientific potential and commercial prospects of its developments in the complex field of neurology.
%20sales%20of%20the%20company%20Longboard%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Longboard-Pharmaceuticals&v=1772610132693 "Schedule of future (projected) sales of the company Longboard Pharmaceuticals")
Future (projected) sales of companies in the market segment - Neuro
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating neurological diseases. This forecast chart reflects the potential future revenue from their pipeline of candidates. This is an analyst's view of the commercial prospects of their drugs for the treatment of epilepsy and other disorders.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772610132708 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Longboard Pharmaceuticals is a biopharmaceutical company focused on developing drugs for rare neurological diseases. Its future depends on the success of its clinical programs. This graph reflects the overall investment climate, but for Longboard, scientific progress in developing therapies for patients who currently lack effective treatment options is key.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772610132709 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Longboard Pharmaceuticals
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare neurological diseases. Its financial performance reflects significant investments in R&D. The chart shows current profitability as an investment in developing drugs for patients who currently have few or no treatment options.
Market segment marginality - Neuro
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for rare neurological diseases. This chart reflects its operating expenses. Future profitability depends on the success of its clinical programs and its ability to develop effective treatments for patients.
Market marginality as a whole
Longboard Pharmaceuticals is a biotech company focused on treating rare neurological diseases. It is currently in clinical trials. This total return chart reflects the investment climate. In a favorable economic environment, the company can more easily attract the capital needed to conduct expensive and time-consuming research.
Employees in the company, segment and market as a whole
Number of employees in the company Longboard Pharmaceuticals
Longboard Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare and severe neurological diseases. This graphic shows its clinical team working to develop new treatments to help patients suffering from epilepsy and other disorders.
Share of the company's employees Longboard Pharmaceuticals within the market segment - Neuro
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for rare neurological diseases. It employs a small but highly qualified team of scientists and clinicians. This chart shows the amount of intellectual capital the company is investing in finding solutions for complex and severe disorders.
Number of employees in the market segment - Neuro
Longboard Pharmaceuticals is a biopharmaceutical company specializing in rare neurological diseases. This chart, showing employment in the neuroscience sector, illustrates the complexity and high demand for treatments for these conditions. For Longboard, the growing number of researchers in this field means both accelerating research and the need to prove the effectiveness of its drugs.
Number of employees in the market as a whole
Longboard Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare neurological diseases. Developing orphan drugs requires significant investment. A strong economy, reflected by the employment growth in this chart, is creating a favorable capital market climate, allowing companies like Longboard to raise funds for long-term clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Longboard Pharmaceuticals (LBPH)
Longboard Pharmaceuticals (LBPH) is a biotech company focused on neurological diseases. This biotech chart is an indicator of concentrated value. Market capitalization is based on expectations for clinical trials and patent value. A small team of scientists can create an asset worth billions.
%20of%20the%20company%20Longboard%20Pharmaceuticals%20(LBPH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Longboard-Pharmaceuticals-LBPH&v=1772610132769 "Chart of market capitalization per employee (in thousands of dollars) of the company Longboard Pharmaceuticals (LBPH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Longboard Pharmaceuticals is a biopharmaceutical company focused on neurological diseases. Its value is determined by its pipeline of potential drugs. This chart demonstrates the high future value the market attributes to its research, based on its small research team.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772610132774 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for rare neurological diseases. Its value depends on the success of its research. This chart for Longboard is a prime example of a biotech company where the market value per employee can be colossal, reflecting the hope of developing a new drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772610132787 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Longboard Pharmaceuticals (LBPH)
Longboard Pharmaceuticals is a biotech R&D company focused on neuroscience. Like its peers in the sector, it is profitless. This chart shows expenses, not revenue: the loss (investment) per employee working on clinical trials and drug development.
%20Chart%20Longboard%20Pharmaceuticals%20(LBPH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Longboard-Pharmaceuticals-LBPH&v=1772610132798 "Company Profit Per Employee (in thousands of dollars) Chart Longboard Pharmaceuticals (LBPH)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Longboard Pharmaceuticals is a biotechnology company developing drugs to treat rare neurological diseases. The effectiveness of a small but highly qualified scientific team is key to its success. This metric demonstrates the value each employee creates, which is an important indicator for assessing the company's potential.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772610132834 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Longboard Pharmaceuticals is a biotech company developing drugs to treat rare neurological diseases such as epilepsy. This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be enormous if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772610132848 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Longboard Pharmaceuticals (LBPH)
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating rare neurological diseases. Since it doesn't yet have commercial products, it has no revenue per employee. This chart clearly illustrates the R&D phase, where the team's entire focus is on conducting clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Longboard-Pharmaceuticals-LBPH&v=1772610132849 "Sales chart per company employee Longboard Pharmaceuticals (LBPH)")
Sales per employee in the market segment - Neuro
Longboard Pharmaceuticals (LBPH) is a biotech company specializing in developing treatments for rare neurological disorders. This chart shows the average revenue per employee in the sector. It is important for assessing R&D efficiency and staffing structure compared to other neuroscience biotechs.
Sales per employee for the market as a whole
Longboard Pharmaceuticals (LBPH) is a clinical-stage biotech company spun out of Arena Pharma, focused on developing drugs for rare neurological disorders. The company has no commercial revenue. This near-zero metric reflects investments in the scientific team conducting clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Longboard Pharmaceuticals (LBPH)
Longboard Pharmaceuticals (LBPH) is a clinical-stage biotech company specializing in rare neurological diseases. This chart shows short interest. The high bearish bets reflect the risks of clinical trials in a complex area (neurology), high cash burn, and concerns about the potential market size for its drugs. (345)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Longboard-Pharmaceuticals-LBPH&v=1772610132879 "Short Shares Chart for the Company Longboard Pharmaceuticals (LBPH)")
Shares shorted by market segment - Neuro
Longboard Pharmaceuticals (LBPH) is a biopharmaceutical company specializing in developing drugs for rare neurological diseases. The chart below represents a general short position in the CNS biotech sector. It demonstrates the investor distrust in the success of complex and lengthy clinical trials.
Shares shorted by the overall market
Longboard Pharma (LBPH) is a clinical-stage biotech company. Its value reflects the hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they require constant refinancing for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Longboard Pharmaceuticals (LBPH)
This Longboard oscillator is a binary bet on the treatment of rare neurological diseases. The company (a spinoff of Arena Pharma) is developing drugs for the treatment of epilepsy. "Overbought" (above 70) occurs in anticipation of or upon the publication of positive clinical trial data. A clinical trial failure or FDA delays lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Longboard-Pharmaceuticals-LBPH&v=1772610132928 "RSI 14 indicator chart for the company's stock Longboard Pharmaceuticals (LBPH)")
RSI 14 Market Segment - Neuro
Longboard (LBPH) is a biotech company specializing in developing drugs to treat severe neurological disorders. This chart measures the "manic-depressive" pulse of the entire Neuroscience sector. It shows when the entire industry is overheated by expectations of a breakthrough or oversold by news of yet another setback.
RSI 14 for the overall market
For Longboard Pharma, a biotech company, this chart is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LBPH (Longboard Pharmaceuticals)
Longboard Pharmaceuticals is a biotech company (spinned out of Arena Pharma) focused on developing drugs to treat rare neurological diseases, including epilepsy. This chart shows the speculative average 12-month price target from analysts based on their assessment of the company's R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LBPH-Longboard-Pharmaceuticals&v=1772610132983 "A chart showing analyst consensus forecasts for the expected stock price. LBPH (Longboard Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price LBPH (Longboard Pharmaceuticals)
Longboard (LBPH) is a biotech company (a spinoff of Arena) focused on developing drugs for rare neurological diseases (epileptics). This chart shows the difference between the market valuation and the consensus estimate. It reflects the potential experts see in their R&D portfolio and the chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LBPH-Longboard-Pharmaceuticals&v=1772610133000 "A chart showing the difference between the consensus forecast and the actual stock price. LBPH (Longboard Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Neuro
Longboard Pharmaceuticals (LBPH) is a clinical-stage biotech company focused on developing therapies for rare and severe neurological conditions, particularly epilepsy. This chart reflects the collective opinion of analysts on the *entire* neurological R&D sector. It shows whether experts believe breakthroughs in the treatment of brain disorders are possible.
Analysts' consensus forecast for the overall market share price
Longboard Pharmaceuticals is a biotech company specializing in developing drugs for the treatment of central nervous system (neurology) diseases. This is a high-risk sector. This chart reflects the overall risk appetite in the market. For LBPH, a clinical-stage company, overall market optimism (the rising chart) is critical for raising capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Longboard Pharmaceuticals
Longboard is an R&D spinoff of Arena Pharma, a biotech R&D company focused entirely on the brain (neurology). Their signature feature is an R&D pipeline of small molecules (pills) targeting rare forms of epilepsy. This chart is a pure R&D barometer of faith/fear. It reflects not sales, but the market's speculative valuation of their (very risky) pipeline and their clinical data.
AKIMA Market Segment Index - Neuro
Longboard Pharmaceuticals is a neurobiotech focused on rare epilepsy disorders. They develop small molecule drugs to control seizures. This chart compares their composite index to the sector, showing how their anti-seizure R&D strategy compares to others.
The AKIM Index for the overall market
Longboard Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of neurological diseases (epilepsy). It is being acquired by Lundbeck. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this successful M&A story compares to overall economic trends.
